Development of a Pharmacokinetic (PK) Model and Assessment of Patient (Pt) Covariate Effects on Dose-Dependent PK Following Different Dosing Schedules in Two Phase I Trials of AP23573 (AP), a mTOR Inhibitor

Journal of Clinical Oncology - United States
doi 10.1200/jco.2005.23.16_suppl.3043
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)


Related search